126 related articles for article (PubMed ID: 36450217)
1. Knowledge-driven design and optimization of potent symmetric anticancer molecules: A case study on PKM2 activators.
Jaiswal E; Globisch C; Jain A
Comput Biol Med; 2022 Dec; 151(Pt B):106313. PubMed ID: 36450217
[TBL] [Abstract][Full Text] [Related]
2. Discovery of boronic acid-based potent activators of tumor pyruvate kinase M2 and development of gastroretentive nanoformulation for oral dosing.
Patle R; Shinde S; Patel S; Maheshwari R; Jariyal H; Srivastava A; Chauhan N; Globisch C; Jain A; Tekade RK; Shard A
Bioorg Med Chem Lett; 2021 Jun; 42():128062. PubMed ID: 33901643
[TBL] [Abstract][Full Text] [Related]
3. The cysteine residue at 424th of pyruvate kinase M2 is crucial for tetramerization and responsiveness to oxidative stress.
Masaki S; Hashimoto K; Kihara D; Tsuzuki C; Kataoka N; Suzuki K
Biochem Biophys Res Commun; 2020 Jun; 526(4):973-977. PubMed ID: 32295714
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2).
Xu Y; Liu XH; Saunders M; Pearce S; Foulks JM; Parnell KM; Clifford A; Nix RN; Bullough J; Hendrickson TF; Wright K; McCullar MV; Kanner SB; Ho KK
Bioorg Med Chem Lett; 2014 Jan; 24(2):515-9. PubMed ID: 24374270
[TBL] [Abstract][Full Text] [Related]
5. Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity.
Chen C; Wang T; Wu F; Huang W; He G; Ouyang L; Xiang M; Peng C; Jiang Q
Drug Des Devel Ther; 2014; 8():1195-210. PubMed ID: 25214764
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic and Structural Insights into Cysteine-Mediated Inhibition of Pyruvate Kinase Muscle Isoform 2.
Srivastava D; Nandi S; Dey M
Biochemistry; 2019 Sep; 58(35):3669-3682. PubMed ID: 31386812
[TBL] [Abstract][Full Text] [Related]
7. Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators.
Li R; Ning X; Zhou S; Lin Z; Wu X; Chen H; Bai X; Wang X; Ge Z; Li R; Yin Y
Eur J Med Chem; 2018 Jan; 143():48-65. PubMed ID: 29172082
[TBL] [Abstract][Full Text] [Related]
8. Activators of PKM2 in cancer metabolism.
Warner SL; Carpenter KJ; Bearss DJ
Future Med Chem; 2014 Jun; 6(10):1167-78. PubMed ID: 25078136
[TBL] [Abstract][Full Text] [Related]
9. Glycolytic reprogramming in cancer cells: PKM2 dimer predominance induced by pulsatile PFK-1 activity.
Shi X; You L; Luo RY
Phys Biol; 2019 Sep; 16(6):066007. PubMed ID: 31469100
[TBL] [Abstract][Full Text] [Related]
10. A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
Arora S; Joshi G; Chaturvedi A; Heuser M; Patil S; Kumar R
J Med Chem; 2022 Jan; 65(2):1171-1205. PubMed ID: 34726055
[TBL] [Abstract][Full Text] [Related]
11. 1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase.
Yacovan A; Ozeri R; Kehat T; Mirilashvili S; Sherman D; Aizikovich A; Shitrit A; Ben-Zeev E; Schutz N; Bohana-Kashtan O; Konson A; Behar V; Becker OM
Bioorg Med Chem Lett; 2012 Oct; 22(20):6460-8. PubMed ID: 22963766
[TBL] [Abstract][Full Text] [Related]
12. Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.
Adnan M; Shamsi A; Elasbali AM; Siddiqui AJ; Patel M; Alshammari N; Alharethi SH; Alhassan HH; Bardakci F; Hassan MI
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361954
[TBL] [Abstract][Full Text] [Related]
13. Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors.
Ye X; Sun Y; Xu Y; Chen Z; Lu S
Med Chem; 2016; 12(7):613-620. PubMed ID: 26951145
[TBL] [Abstract][Full Text] [Related]
14. Pyruvate kinase activators as a therapy target: a patent review 2011-2017.
Adem S; Comakli V; Uzun N
Expert Opin Ther Pat; 2018 Jan; 28(1):61-68. PubMed ID: 28994333
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel sulfonamide derivatives containing pyridin-3-ylmethyl 4-(benzoyl)piperazine-1-carbodithioate moiety as potent PKM2 activators.
Li R; Ning X; He J; Lin Z; Su Y; Li R; Yin Y
Bioorg Chem; 2021 Mar; 108():104653. PubMed ID: 33517002
[TBL] [Abstract][Full Text] [Related]
16. Targeting pyruvate kinase muscle isoform 2 (PKM2) in cancer: What do we know so far?
Chhipa AS; Patel S
Life Sci; 2021 Sep; 280():119694. PubMed ID: 34102192
[TBL] [Abstract][Full Text] [Related]
17. SIRT2-Mediated Deacetylation and Tetramerization of Pyruvate Kinase Directs Glycolysis and Tumor Growth.
Park SH; Ozden O; Liu G; Song HY; Zhu Y; Yan Y; Zou X; Kang HJ; Jiang H; Principe DR; Cha YI; Roh M; Vassilopoulos A; Gius D
Cancer Res; 2016 Jul; 76(13):3802-12. PubMed ID: 27197174
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analyses of the cysteine thiol oxidation of PKM2 reveal the effects of multiple oxidation on cellular oxidative stress response.
Irokawa H; Numasaki S; Kato S; Iwai K; Inose-Maruyama A; Ohdate T; Hwang GW; Toyama T; Watanabe T; Kuge S
Biochem J; 2021 Apr; 478(7):1453-1470. PubMed ID: 33749780
[TBL] [Abstract][Full Text] [Related]
19. Structural Investigation of a Dimeric Variant of Pyruvate Kinase Muscle Isoform 2.
Srivastava D; Razzaghi M; Henzl MT; Dey M
Biochemistry; 2017 Dec; 56(50):6517-6520. PubMed ID: 29182273
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic activation of PKM2 slows lung tumor xenograft growth.
Parnell KM; Foulks JM; Nix RN; Clifford A; Bullough J; Luo B; Senina A; Vollmer D; Liu J; McCarthy V; Xu Y; Saunders M; Liu XH; Pearce S; Wright K; O'Reilly M; McCullar MV; Ho KK; Kanner SB
Mol Cancer Ther; 2013 Aug; 12(8):1453-60. PubMed ID: 23720766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
